SLU-PP-332 Peptide Pen, 1.3mg
Product Overview
SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), a family of nuclear receptors involved in mitochondrial and metabolic gene expression.
It is studied as an exercise mimetic, meaning a compound investigated for whether it activates some of the same cellular pathways that endurance exercise does. That is the research question. It is not a finding, and it is not a substitute for training.
Worth saying plainly: SLU-PP-332 is a new compound with a correspondingly thin evidence base. The published work is preclinical and largely in rodents. There are no human trials establishing safety, dosing or effect. Anyone reading confident claims about what this compound does in people is reading marketing.
Product Specifications
- Active ingredient: SLU-PP-332
- Total amount: 1.3mg
- Format: Pre-filled multi-dose pen
- Supplied reference: 9 clicks per 50mcg, approximately 26 doses per pen
- Administration: Subcutaneous
- Regulatory status: Research use only. Not a registered medicine in South Africa and not evaluated by SAHPRA.
Mechanism of Action
The estrogen-related receptors are transcription factors. Despite the name they are not activated by oestrogen, and research into them concerns energy metabolism rather than reproductive biology.
Research into ERR agonism has examined pathways associated with:
- Mitochondrial biogenesis
- Oxidative phosphorylation gene expression
- Fatty-acid oxidation
- Energy expenditure
- Skeletal-muscle metabolic adaptation
- Exercise-associated signalling
These are the pathways under investigation. Whether activating them produces any particular outcome in a human being is precisely what has not been established.
Research Applications
SLU-PP-332 research includes:
- ERR receptor signalling
- Mitochondrial biogenesis
- Exercise-mimetic research
- Fatty-acid oxidation
- Energy expenditure
- Metabolic adaptation
Dosage & Administration
The following is the supplied product dosing reference. It is the manufacturer’s stated research reference and not recommended human dosing, because no such dosing has been established.
- Per dose: 9 clicks, approximately 50mcg
- Supplied frequency: twice daily, morning and evening
- Doses per pen: approximately 26 at the above reference
Administration
- Inspect the solution. It should be clear and colourless.
- On first use, prime the pen by dialling 9 clicks and pressing until a drop appears at the tip.
- Dial the required number of clicks.
- Prepare the administration site.
- Administer subcutaneously and hold for several seconds.
- Remove and safely dispose of the needle.
- Replace the cap and rotate administration sites.
Considerations
Because there is no human safety data for this compound, the honest position is that its side-effect profile in people is unknown. Reported observations in research settings include injection-site irritation and changes in energy levels.
Anyone researching a compound at this stage of investigation should be aware that an absence of reported effects is not the same as evidence of safety.
Storage & Handling
- Store refrigerated where required, or within the manufacturer’s specified temperature range.
- Never freeze.
- Keep the pen capped and protected from light and excessive heat.
- Keep out of reach of children.
- Do not use beyond the stated expiry date.
- Do not use if the solution is cloudy, discoloured or contains visible particles.
Important Notice
SLU-PP-332 is an investigational compound with a preclinical evidence base. It is not a registered medicine in South Africa and has not been evaluated by SAHPRA.
Nothing above is a therapeutic claim. This product is not intended to diagnose, treat, cure or prevent any disease.
For research use only. Not intended for human consumption.
